Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc.

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $8.00. Newman covers t...

Market Cap	$98.08M	P/E Ratio	N/A
52W High	$1.19	52W Low	$0.45
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	12.7%	52W Position	20.9%
Overall Score	42	Value Score	60
Quality Score	--	Technical Score	25

EPS Current Est	$-1.05	EPS Next Est	$-0.79
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACET	$0.60	+4.29%	981.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACET	$0.60	+4.3%	981.86K
3
4
5
6

ACET

ACET

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Adicet Bio Inc. Data in Excel

Get Adicet Bio Inc. Data in Excel